BAMF (Biomarker Amplification Filter) shows promise for early MS (multiple sclerosis) diagnostic:
This article was originally published in Clinica
Eclipse Diagnostics, a subsidiary of Large Scale Biology (LSB), says that evidence shows that its BAMF technology (Biomarker Amplification Filter) could lead to early diagnosis of multiple sclerosis (MS) and other life-threatening diseases. In a presentation last week at the American Academy of Neurology Meeting, in San Francisco, California, researchers using the BAMF technology reported the presence of distinct proteomic signatures in blood serum from MS patients. According to Vacaville, California-based LSB, findings from the study, entitled, "A Blood Test to Diagnose Multiple Sclerosis: Use of MALDI/TOF and Serum Proteomic Pattern Analysis", provide "further confirmation that the BAMF technology will lead to early diagnosis of diseases such as multiple sclerosis and various cancers."